Bengaluru: Syngene International Limited has announced key changes in its senior management, inducting five leaders into its Executive Committee with effect from August 20, 2025.
The company has appointed Ajay Tandon, Head of Strategy and Corporate Development; Gaurav Kushwaha, Chief Technology Officer; Dr. Mrinal Kammili, Head of Translational and Clinical Research; Dr. Subhendu Kumar, Head of Chemistry; and Dr. Priyaranjan Pattanaik, Head of Biology, as members of the Executive Committee.
Ajay Tandon brings more than 30 years of leadership
experience spanning life sciences, private equity, and
banking. He focuses on envisioning business potential,
strategic planning, and managing execution. Driven by
a passion for innovation and growth, he thrives on
engaging with people, ideas, and challenges. Renowned
for his integrity and perseverance, Ajay cultivates
enduring, trust-based relationships.
experience spanning life sciences, private equity, and
banking. He focuses on envisioning business potential,
strategic planning, and managing execution. Driven by
a passion for innovation and growth, he thrives on
engaging with people, ideas, and challenges. Renowned
for his integrity and perseverance, Ajay cultivates
enduring, trust-based relationships.
Gaurav Kushwaha is a digital transformation leader with
more than twenty years of experience across telecom,
banking, Defense, pharma, chemicals, and
manufacturing. He specializes in designing and
implementing IT and digital strategies that drive EBITDA
impact, reduce costs, and enhance business processes,
earning over 20 global recognitions, including DEMING
and Lighthouse awards.
more than twenty years of experience across telecom,
banking, Defense, pharma, chemicals, and
manufacturing. He specializes in designing and
implementing IT and digital strategies that drive EBITDA
impact, reduce costs, and enhance business processes,
earning over 20 global recognitions, including DEMING
and Lighthouse awards.
Dr. Mrinal Kammili is a senior healthcare professional
with more than 27 years of experience across
healthcare, pharmaceuticals, clinical research, and life
sciences. As a medical doctor, PhD holder, and AHAqualified intensivist, he blends clinical expertise with
strong leadership to foster organizational growth and
deliver client-centric value.
with more than 27 years of experience across
healthcare, pharmaceuticals, clinical research, and life
sciences. As a medical doctor, PhD holder, and AHAqualified intensivist, he blends clinical expertise with
strong leadership to foster organizational growth and
deliver client-centric value.
Dr. Subhendu Kumar is an experienced medicinal
chemist specializing in GPCR and oncology drug
discovery. He has successfully led CRO projects
involving more than 20 chemists to deliver leadoptimized candidates and possesses extensive
experience in library synthesis of over 1,000
compounds. His expertise covers organic and medicinal
chemistry, biology, ADMET, and drug discovery,
supported by strong communication skills and
collaborative leadership.
chemist specializing in GPCR and oncology drug
discovery. He has successfully led CRO projects
involving more than 20 chemists to deliver leadoptimized candidates and possesses extensive
experience in library synthesis of over 1,000
compounds. His expertise covers organic and medicinal
chemistry, biology, ADMET, and drug discovery,
supported by strong communication skills and
collaborative leadership.
Dr. Priyaranjan Pattanaik, Ph.D., is a seasoned scientist
and business leader with over 23 years of experience in
pharmaceuticals and biotech within the CRO/CDMO
space. With deep expertise in biotherapeutics—
including antibodies, bispecifics, ADCs, peptides,
proteins, and cell/gene therapies—he has led programs
from discovery through clinical development. A
passionate mentor and advocate for innovation, he
brings strong scientific leadership and talent
development skills.
and business leader with over 23 years of experience in
pharmaceuticals and biotech within the CRO/CDMO
space. With deep expertise in biotherapeutics—
including antibodies, bispecifics, ADCs, peptides,
proteins, and cell/gene therapies—he has led programs
from discovery through clinical development. A
passionate mentor and advocate for innovation, he
brings strong scientific leadership and talent
development skills.
